The FDA recently approved Vyvanse (lisdexamfetamine) for the treatment of moderate to severe binge eating disorder (BED) in adults. Vyvanse is a central nervous system stimulant that was already approved for attention deficit hyperactivity disorder (ADHD) in adults and children aged 6 and older. This new approval gives doctors another option to help adults who struggle with binge eating episodes.
Vyvanse is not a weight loss drug. The FDA specifically states that it is not indicated for weight loss, and its safety and effectiveness for obesity have not been established. The approval is based on clinical studies that showed Vyvanse can reduce the number of binge eating days in adults with BED.
The recommended starting dose for BED is 30 mg once daily. Your doctor may increase the dose by 20 mg each week to a target of 50 to 70 mg per day, but not more than 70 mg. If binge eating does not improve, your doctor may advise stopping the medication.
If you think Vyvanse might be right for you, talk to your doctor. They can help you understand the benefits and risks, and decide if this treatment fits your health needs. Always follow your doctor's guidance and never change your dose without consulting them.